HROW
Harrow Health, Inc.
HROW offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over HROW overall, supported by stronger fundamentals and lower modeled downside.
HROW Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Weak |
HROW's revenue is currently strong, but its profitability, cash flow and balance sheet are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
HROW PE Valuation
HROW has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 26x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
HROW Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect HROW to return to profit, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
HROW Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.10 | — |
| Q3 2026 | -$0.75 | -$0.60 |
| Q2 2026 | -$0.97 | -$0.67 |
| Q1 2026 | -$0.38 | +$0.23 |
| Q4 2025 | -$0.14 | +$0.35 |
| Q3 2025 | -$0.15 | +$0.79 |
| Q2 2025 | -$0.30 | +$0.65 |
| Q1 2025 | -$0.61 | +$0.30 |
| Q4 2024 | -$0.49 | +$0.26 |
HROW lost $0.75 per share over the past year, a bigger loss than the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over HROW on earnings quality, reporting a profit while its opponent remains loss making.
HROW Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $99.3M | +39% |
| Q2 2026 | $70.7M | +11% |
| Q1 2026 | $44.2M | -7.6% |
| Q4 2025 | $89.1M | +33% |
| Q3 2025 | $71.6M | +45% |
| Q2 2025 | $63.7M | +30% |
| Q1 2025 | $47.8M | +38% |
| Q4 2024 | $66.8M | +84% |
HROW's revenue is growing: $99M last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 12% | -9 points |
| Q2 2026 | -16% | -34 points |
| Q1 2026 | -50% | -27 points |
| Q4 2025 | 18% | -1.8 points |
| Q3 2025 | 21% | +18 points |
| Q2 2025 | 18% | +15 points |
| Q1 2025 | -23% | -3.4 points |
| Q4 2024 | 19% | +33 points |
HROW has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over HROW on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
HROW Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9M | -155% |
| Q2 2026 | -$10.2M | -$9.3M |
| Q1 2026 | -$9.2M | -147% |
| Q4 2025 | $8.1M | +$26.4M |
| Q3 2025 | $16.4M | +598% |
| Q2 2025 | -$969K | +$2.1M |
| Q1 2025 | $19.5M | +$24.2M |
| Q4 2024 | -$18.3M | -316% |
HROW's free cash flow was −$20M over the past year, against $17M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over HROW on cash generation, producing positive trailing cash flow while its opponent burns cash.
HROW Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.2% | +1.2M shares |
| 1 year | -0.9% | -341K shares |
| 3 years | +12% | +4.3M shares |
| 5 years | +42% | +11.4M shares |
| Available history | +46% | +12.1M shares |
HROW has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HROW Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 9.7x | High |
| Q4 2025 | 5.5x | High |
| Q3 2025 | 9.3x | High |
| Q2 2025 | 12.2x | High |
| Q1 2025 | 29.7x | High |
| Q4 2024 | 20.2x | High |
| Q4 2023 | 88.0x | High |
| Q3 2023 | 37.2x | High |
HROW's net debt is about 9.7 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
HROW Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.2 | Neutral |
| Stochastic | 9.8 | Oversold |
HROW's weekly RSI is 38 (neutral) and its Stochastic is 10 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
HROW PE vs Healthcare Sector
| Metric | HROW | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HROW has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HROW Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.0 | 2.4% below |
| 20 week MA | $35.3 | 20% below |
| 50 week MA | $39.0 | 27% below |
| 100 week MA | $36.1 | 21% below |
| 200 week MA | $28.8 | 1.6% below |
HROW is in a downtrend: it's below all five of its weekly moving averages, and 1.6% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over HROW on trend strength, trading above more of its moving averages.
HROW Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.88 | $5.78 | -27% |
| 2021 | $5.78 | $9.20 | +59% |
| 2022 | $9.20 | $14.2 | +54% |
| 2023 | $14.2 | $11.2 | -21% |
| 2024 | $11.2 | $33.5 | +199% |
| 2025 | $33.5 | $50.1 | +50% |
| 2026 YTD | $50.1 | $28.3 | -44% |
HROW is down 44% so far in 2026, after finishing higher in four of the previous six years.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over HROW on returns for 2026, with the stronger performance.